

4th International Conference and Exhibition on **BIOSENSOTS & BIOELECTRONICS**

September 28-30, 2015 Atlanta, USA



New SPR-based biosensor platform for fragment-based-drug-discovery

The detection and characterization of fragment binding events is dependent upon sensitive biophysical technologies capable of detecting low affinity interactions of low molecular weight compounds. Current Surface-Plasmon-Resonance based biosensors are limited in the processing and subsequent data analyses of fragment binding events. A new Surface Plasmon Resonance – based platform has been developed to specifically address binding analysis requirements in fragment screening. New injection techniques and data analysis methods illustrating rapid and automated hit selection capabilities will be presented. At the heart of the new platform is a new gradient concentration technique that allows affinity values to be obtained with single injections. Rapid hit selection identification is performed using a new statistical analysis method which allows data analysis to be competed in minutes. Relevant industry case studies will be highlighted to demonstrate fragment screening workflow optimization. The new platform potentially offers researchers a significant advancement in workflow and minimized assay development substantially over conventional SPR platforms used in fragment-based-drug-discovery.

Biography

Tom Jobe holds BS and MS Engineering degrees from Oklahoma State University. He spent 11 years in the energy business as an instrument developer and 25 years as a developer and manager of medical diagnostic instruments with Organon Teknika & BioMerieux, where he led the development of microbiology, coagulation, and nucleic acid diagnostics instrumentation. He currently is the Chief Operating Officer of SensiQ Technologies and has directed the R&D and Manufacturing operations for the company's life sciences instrumentation and commercialization efforts for the past 10 years.

tom.jobe@sensiqtech.com

Notes: